CPA CFA - Pharmaron Beijing CFO Board
| 300759 Stock | 26.95 0.23 0.86% |
CFO
CPA CFA is CFO Board of Pharmaron Beijing Co
| Age | 46 |
| Address | Building 1, Beijing, China, 100176 |
| Phone | 86 10 5733 0087 |
| Web | https://www.pharmaron.com |
Pharmaron Beijing Management Efficiency
The company has return on total asset (ROA) of 0.0415 % which means that it generated a profit of $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1358 %, meaning that it generated $0.1358 on every $100 dollars invested by stockholders. Pharmaron Beijing's management efficiency ratios could be used to measure how well Pharmaron Beijing manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Other Assets is expected to grow to about 366.6 M, whereas Total Assets are forecasted to decline to about 13.6 B.Similar Executives
| Found 2 records | CFO Age | ||
| Hua Wang | PetroChina Co Ltd | 49 | |
| Jiawen Peng | China Merchants Bank | 55 | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0415 |
Pharmaron Beijing Leadership Team
Elected by the shareholders, the Pharmaron Beijing's board of directors comprises two types of representatives: Pharmaron Beijing inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharmaron. The board's role is to monitor Pharmaron Beijing's management team and ensure that shareholders' interests are well served. Pharmaron Beijing's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharmaron Beijing's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jingqi Huang, Senior Pharmacology | ||
| Jane Zhang, Chief Services | ||
| Celina Zhong, Senior Resources | ||
| Mandy Xu, Senior DMPK | ||
| Connie Sun, Senior Development | ||
| Stephen Lewinton, Senior Operations | ||
| Sid Bhoopathy, Senior CGT | ||
| Antony Davies, Senior CMC | ||
| Hua Yang, Chief Manager | ||
| Bei MA, Exec Director | ||
| Xiaoqiang EMBA, President CoFounder | ||
| Xiaoqiang Lou, COO President | ||
| Boliang Lou, Chairman CEO | ||
| CPA CFA, CFO Board | ||
| Henry Tang, Vice Affairs | ||
| MBA MBA, Senior Resources | ||
| MA MA, Executive Director |
Pharmaron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharmaron Beijing a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0415 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 46.66 B | ||||
| Shares Outstanding | 1.49 B | ||||
| Shares Owned By Insiders | 42.12 % | ||||
| Shares Owned By Institutions | 21.88 % | ||||
| Price To Book | 3.57 X | ||||
| Price To Sales | 3.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pharmaron Stock
Pharmaron Beijing financial ratios help investors to determine whether Pharmaron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaron with respect to the benefits of owning Pharmaron Beijing security.